NCT04893135View on ClinicalTrials.gov

"Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes"

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 11, 2021

Primary Completion Date

October 11, 2022

Study Completion Date

October 11, 2022

Conditions
Type II Diabetes
Interventions
OTHER

pratice physical activity

treadmill walking : walk at a speed of 2.7 km.h-1 in 3 stages of 3 mins with an incline of 0%, 5% and 10%

Trial Locations (1)

91100

Centre Hospitalier Sud Francilien, Corbeil-Essonnes

All Listed Sponsors
lead

Centre Hospitalier Sud Francilien

OTHER

NCT04893135 - "Impact of the Rapid Normalization of Chronic Hyperglycemia and the Practice of Moderate Physical Activity on the Receptor Activator of Nuclear Factor-kappa B Ligand / Osteoprotégérine (RANKL / OPG) System in Patients Living With Type II Diabetes" | Biotech Hunter | Biotech Hunter